So AMGN misses earnings, fails a phase 3 safety study and barely goes down on either event. Biogen beats earnings, acquires a phase 3 start up and has dropped $45 in a month. Makes sense.
Would paying out a dividend help? I'd rather they acquire like they are doing, but the stock is complete garbage right now. It needs something to lift it.
RALLLLLLLLLYYYYYYYYYYYY ..CHEAPEST BIOTECH HERE (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
AXS-05 Treatment Resistant Depression in Phase 3......Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.
AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3.......No approved medication = unmet medical need. 2M patients in the U.S.
AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status).......No approved drug = high unmet need. 80,000 new cases per year in the U.S.
AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track).........7M patients in the U.S.
AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 ......1.6M patients in the U.S.
why it continue down, any good suggestion for what should I do, thanks
In all seriousness, where do you guys think the bottom is? Last couple of times it tanked, it went all the way to $225. Goes through all support levels like nobodies business. I think this has been down every day since earnings except maybe 3! Aside from the one day that it went up $4 on the purchase, the other 2 days were < $1 following long losing streaks.
whooz yor daddy
I'm beginning to understand why our grandparents stashed money under their mattresses!
looking at the 1yr price trend, seems the support at 250 was expected yet the overall trend is in a tight channel downwards. Any ideas when this might stop? are there any potential catalysts before next year Alzheimer's ? ( itself a long shot) or is my beloved biib becoming a gild?
yeah,went from 251 to 260. I should have bailed.
whooz yor daddy
Appeals court holds lower court's dismissal of investors suit against Biogen. A bit of good news is always welcome.
this POS better hold 250 or were in deep sheet.
Biogen didn't hold above $259 but that was largely market forces rather than the stock itself .. Technically and on daily frame, $255 is an important threshold to establish now to be followed by $260 but more critical is to hold above $268-270 price ..
The Money Flow index, crucial indicator, is showing "signs" that the worst is behind us and its well supported by both Wm%R and CCI .. MACD & Full STO still didn't confirm positive signals although seem close
On the daily frame, all key Tech. Indicators including CCI, Wm%R, RSI and both Fast & Slow Stochastic are giving entry point around current price +/- &3 for BIIB .. Yet the MFI & MACD are not there exactly yet although close .. unless something fundamental happens i think at or around $250 is excellent price
Why is BIIB dropping like its hot? I thought 250 was bottom?
almost 260. can't hold the gains
this,junk is dead
whooz yor daddy
7:51 AM EDT, 05/15/2017 (MT Newswires) -- Biogen (BIIB) said pre-market Monday it completed an asset purchase of Remedy Pharmaceuticals' phase 3 candidate, CIRARA. The target indication for CIRARA is large hemispheric infarction, a severe form of ischemic stroke. Biogen will pay a $120 million upfront payment plus potential milestone and royalty payments.
I'll hold on to this till 300, it's on sale now.
BIIB successfully passed low 250, next key level is to hold above 259 then above 263 .. Price at 270 represents stronger resistance and hopefully will continue to 295
This Fund#$%$ Gained 200% In A Year And Why No One Knows About It$MDCO $BIIB $ABBVhttp://www.insidermonkey.com/blog/this-funds-picks-gained-200-in-a-year-and-why-no-one-knows-about-it-581306/?utm_source=Stocktwits&utm_medium=Social&utm_campaign=dnan